Raymond James bullish rating for Bausch Health Companies (Bausch Health Companies NAME Stock Quote, Chart, News, Analysts, Financials NYSE:BHC) remains unchanged after a U.S. District Court ruling on April 17, which granted summary judgment in favour of Bausch Health and Teva, denying Norwich Pharmaceuticals’ attempt to launch a generic version of Xifaxan before January 2028. […]
Raymond James analyst Michael W. Freeman thinks NervGen Pharma (NervGen Pharma Corp Stock Quote, Chart, News, Analysts, Financials TSXV:NGEN) is undervalued. In a research update to clients April 8th, the analyst maintained his “Outperform” rating and target price of $4.50 per share on the stock. At a recent event, NervGen highlighted the urgent need for […]
Share
Tweet
Share
